Xiao Gan Shi

Researchers are evaluating a new treatment regimen called MAAZA, which combines mitoxantrone hydrochloride liposomes with cytarabine and azacitidine, for adults newly diagnosed with primary Acute Myeloid Leukemia AML. This study compares the MAAZA regimen with the traditional DAAZA chemotherapy regimen to assess their effectiveness and safety in improving treatment outcomes for AML patients. The trial is a prospective, multicenter, randomized controlled study aiming to provide high-quality clinical evidence to improve AML treatment and prognosis. Participants are randomly assigned to one of two treatment groups. The MAAZA group receives mitoxantrone hydrochloride liposome 24 mgm2 intravenously on day 1 every 4 weeks, cytarabine 100 mgm2 intravenously every 12 hours for 7 days, and azacitidine 100 mg subcutaneously once daily for 7 days. The comparison group receives daunorubicin 60 mgm2 intravenously once daily for 3 days, cytarabine 100 mgm2 intravenously every 12 hours for 7 days, and azacitidine 100 mg subcutaneously once daily for 7 days. Each treatment cycle lasts 28 days. During the study, participants undergo evaluations including complete remission rates 2 to 3 weeks after the first treatment cycle. Researchers also monitor adverse events, remission rates, survival times, and mortality up to 100 months after randomization. Regular assessments include blood tests and physical health evaluations. The study lasts for multiple cycles and includes long-term follow-up to assess the overall impact of the treatments on patient survival and disease progression.

Researchers are evaluating an artificial intelligence-based multimodal cognitive screening system to identify mild cognitive impairment MCI related to diabetes early in patients with type 2 diabetes mellitus T2DM. This observational study follows participants for 3 to 5 years to assess the systems accuracy and feasibility. The study also explores how diabetic metabolic indicators, such as glycemic variability and HbA1c levels, relate to changes in cognitive function, aiming to improve early detection and intervention for cognitive decline in T2DM patients. Participants are observed without additional interventions over the 3 to 5 years of follow-up. The study includes groups of participants with normal cognition and those with mild cognitive impairment. Cognitive status data are collected at the beginning and end of the study period, with no study drug or treatment administered. During the study, participants undergo cognitive assessments and monitoring of diabetic metabolic factors. Researchers measure the accuracy of the AI screening system in early detection and track the rate of cognitive decline over the follow-up period. The study also evaluates the predictive value of combining multiple types of data. Participants remain under observation with regular assessments, helping to understand the relationship between diabetes and cognitive changes over time.

Nausea and vomiting in pregnancy NVP is a common and challenging problem during the first trimester, affecting the quality of life for many pregnant women. This research aims to evaluate the clinical effectiveness and safety of thumbtack needle TN therapy, a type of acupuncture, for treating NVP. The study is a multi-center, large-sample, randomized, controlled, and triple-blinded clinical trial designed to provide high-quality evidence on this treatment. The trial compares thumbtack needle therapy with a sham thumbtack needle treatment. TN involves applying small intradermal needles to specific acupuncture points, which are kept in place for 3 days with patients pressing the needles multiple times daily. Treatments occur every 3 days for a total of 5 sessions over 15 days. The sham treatment mimics the procedure without actual needle penetration and without pressing during retention. Participants will be closely monitored throughout the study with assessments including nausea and vomiting severity, quality of life, anxiety, depression, sleep quality, weight changes, blood tests for electrolytes, liver and kidney function, thyroid hormones, and pregnancy and neonatal outcomes. Safety and patient satisfaction will also be evaluated. The primary outcome is the change in nausea and vomiting severity measured by the PUQE scale from baseline to day 15. Follow-up continues up to 42 days postpartum to observe pregnancy complications and neonatal health.